Trial Profile

A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 06 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ligelizumab (Primary) ; Histamine H1 receptor antagonists
Indications Chronic urticaria
Focus Therapeutic Use
Sponsors Novartis; Novartis Healthcare; Novartis Pharma; Novartis Pharma A.G.; Novartis Pharmaceuticals

04 Feb 2024 This trial has been discontinued in Italy according to European Clinical Trials Database record.
20 Feb 2023 This trial has been completed in Estonia (end date of the trial : 01-Sep-2022), according to European Clinical Trials Database record
31 Jan 2023 Status changed from completed to discontinued.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com